13F Holdings
中文EN

NGEN NERVGEN PHARMA CORP. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1751912 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-81.9%
TTM EPS YoY-69.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,457.6%
ROA-206.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets85.0%
Debt / equity0.00x
Current ratio1.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-115.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense13.91M15.81M
SG&A expense11.17M9.37M
Net income-44.12M-24.25M
EPS (basic)-0.61-0.36
EPS (diluted)-0.61-0.36
Weighted avg. shares (diluted)72.33M67.32M
Balance sheet
Cash & equivalents22.07M17.27M
Receivables80,825415,301
Current assets22.80M19.01M
Intangibles409,163464,958
Total assets23.21M19.49M
Current liabilities19.73M16.90M
Total liabilities19.73M16.91M
Shareholders' equity3.48M2.58M
Shares outstanding79.65M70.33M
Cash flow statement
Operating cash flow-19.50M-16.84M
Investing cash flow100,92658,874
Financing cash flow23.76M22.70M
Stock-based compensation5.39M6.04M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.